Glenmark Launches Generic Olanzapine Injection in US, Targets USD 25.4 Million Market

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals Inc., USA, said, "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers."

The company noted that its Olanzapine for Injection, 10 mg/vial, Single-Dose Vial is approved only for the indications listed in Glenmark's approved prescribing information. It also clarified that the IQVIA market data reflects sales across all approved indications of the reference listed drug and available therapeutic equivalents, while Glenmark's product will be marketed only for its approved indications.